Contact

Biotechnology in Spain finds investors


,
Integral service around a transaction
BY : Diego GutiérrezSeptember Tue, 2014
bioUna de las principales barreras del crecimiento de las empresas biotecnológicas españolas es su reducido tamaño (>95% menos de 250 empleados) que les impide acelerar la salida a mercados exteriores por ejemplo. La principal causa de este reducido tamaño se debe a la escasez de financiación o inversión privada. Aunque se está generando un ecosistema nacional de capital riesgo biotecnológico especializado y cada vez se cierran más operaciones con inversores extranjeros, son muchos los deberes que quedan por mejorar.

El 50%  de las rondas están orientadas a procesos de expansión

Slide 2

Teniendo en cuenta que del 10% de las rounds no se ha revelado el tipo de operación, es significativo que el 50% de ellas se hayan dedicado a planes de expansión y crecimiento. El siguiente grupo lo ocupan las empresas en sus fases iniciales (semilla, startup o spinof) suponiendo un 20% de las operaciones. Esto refleja que el sector no es un sector maduro, que presenta expectativas de crecimiento a los investors y que las operaciones de consolidación son escasas.

Destaca la operación de buildup, dentro de las actividades de la metabolómica protagonizada en el 2010 por la empresa vasca OWl genomics that bought la empresa guipuzcoana MD Renal. Desde entonces, OWl, empresa participada mayoritariamente por CRB, asumió la gestión de la nueva filial.

Cataluña y Madrid concentran el 50% de las empresas financiadas

Slide 3

De todas las empresas analizadas del sector biotecnológico que han recibido rondas los últimos años (un total de 107 empresas), casi la mitad de ellas tienen su sede entre Cataluña (31 empresas) y Madrid (20 empresas). Las siguientes  C.C.A.A. que lideran el ranking son País Vasco, Andalucía y Navarra. El liderazgo de Cataluña puede deberse a la tracción que supone el ecosistema de las empresas farmacéuticas situadas en Barcelona.

La aparición de Navarra en el top5, es un reflejo de la influencia que ha supuesto la University of Navarra y sus centros de investigación en la rama bio-sanitaria en el desarrollo de nuevas empresas en el sector.

Other related links:

Listado de inversores biotecnológicas España

List of investors in biomarker biotechnology

We are currently preparing a report on the current state of crowdfunding as an alternative means of financing. If you are interested in receiving this report, please leave us your email address.

 

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu